Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture.
J Pharmacol Sci
; 123(2): 110-9, 2013.
Article
in En
| MEDLINE
| ID: mdl-24096833
ABSTRACT
Hyperlipidemia is referred to as hypercholesterolemia, hypertriglyceridemia, or both in combined hyperlipidemia. Here, a novel mouse model of combined hyperlipidemia is described. Mice were orally given a single dose of a modeling agent (MA) made of a mixture of schisandrin B/cholesterol/bile salts (1/2/0.5 g/kg) suspended in olive oil. MA treatment increased serum triglycerides (TG) and total cholesterol (TC) (up to 422% and 100% at 12 - 96 h post-treatment, respectively) and hepatic TG and TC (up to 220% and 26%, respectively) in a time- and dose-dependent manner, associated with elevation of high-density lipoprotein and low-density lipoprotein levels. Serum alanine/aspartate aminotransferase activities, indicators of liver cell damage, were also elevated (up to 198%) at 48 and 72 h post-MA treatment. Fenofibrate blocks MA-induced hyperlipidemia, lipid accumulation in the liver, as well as liver injury. Oral administration of a mixture of schisandrin B, cholesterol, and bile salt could generate an interesting mouse model of combined hyperlipidemia associated with hepatic steatosis and steatohepatitis.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Polycyclic Compounds
/
Bile Acids and Salts
/
Cholesterol
/
Lignans
/
Disease Models, Animal
/
Fatty Liver
/
Chemical and Drug Induced Liver Injury
/
Hyperlipidemias
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Animals
Language:
En
Journal:
J Pharmacol Sci
Journal subject:
FARMACOLOGIA
Year:
2013
Document type:
Article
Affiliation country:
China
Country of publication:
JAPAN
/
JAPON
/
JAPÃO
/
JP